Evolent Health Earnings: What To Look For From EVH

Evolent Health (EVH) reports earnings Thursday before market hours. Last quarter, it posted revenue of $496.2M, up 2.6% YoY, missing analysts’ revenue expectations, while EPS beat. For the upcoming quarter, analysts expect revenue growth of 34.3% YoY. EVH is down 46.1% over the past month versus an average peer gain, with an analyst price target of $5.83.

Original reporting
Published Aug 5, 2026, 4:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 4:23 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Evolent Health Earnings: What To Look For From EVH — source image
Decision brief

The 30-second read

$EVHNeutralMed
01

Why it matters

Traders should treat this as a revenue-quality and guidance-risk event, since the article emphasizes prior revenue estimate misses and a large recent drawdown in EVH shares.

02

Market read

EVH’s earnings timing and the stated consensus revenue growth rate set up a near-term catalyst, with heightened sensitivity to whether revenue re-accelerates after prior misses.

03

What to watch

The piece does not include guidance details, margin trends, or contract/customer metrics, which are often the real drivers of post-earnings repricing.

Relevance 5/10Novelty 4/10Timing: Thursday before market hours earnings setup

Background

The article is a pre-earnings checklist for Evolent Health, referencing its last quarter results and the Street’s expectations for the upcoming report.

Company-level read

Ticker impact

$EVHNeutralMedium confidence
Context

Evolent Health (EVH) is set to report earnings Thursday pre-market, with the article citing recent revenue misses and a 34.3% YoY growth expectation.

Expected impact

High dispersion risk around the print, with upside if revenue growth and EPS beat the article’s expectations, downside if revenue again misses.

Evidence & confidence

The text provides consensus growth (34.3% YoY) and notes multiple prior revenue misses, implying traders will focus on revenue trajectory and guidance quality rather than EPS alone.

Market effects

Highlights healthcare technology earnings sensitivity, referencing Omnicell’s results and the sector’s recent average share-price strength.

No explicit regional impact described.

No explicit global impact described.

Counterpoint

Despite the revenue-miss history, the article notes EPS beat in the last quarter, so the market may reward profitability even if revenue remains choppy.

Key entities

  • Evolent Health

    Healthcare solutions company scheduled to report earnings Thursday before market hours; recent history includes revenue estimate misses and a prior EPS beat.

  • Omnicell

    Peer mentioned as having reported results first, with revenue beating estimates but the stock down 14.6%.

Related articles

$EVHMed

EVH Q2 2026 Deep Dive: Oncology Suite and AI Automation Drive Growth Amid Membership Headwinds

Evolent Health (EVH) reported Q2 CY2026 revenue of $652.5 million, up 46.9% year on year, beating Wall Street expectations. Full-year revenue guidance of $2.65 billion at the midpoint was 5.9% above analysts’ estimates. Non-GAAP EPS was $0.02. Management cited Highmark contract launch, renewals, and scaling of its Auth Intelligence AI automation, while noting Medicaid and exchange membership headwinds.

$EVHMedAI 8/10

Why is Evolent Health stock surging today?

Evolent Health (EVH) shares rose 23.4% in pre-market after the company reported Q2 2026 results. According to the article, EPS was $0.02 versus -$0.01 expected, and revenue was $652.52M versus $597.46M expected, up about 47% year over year. The move was linked to short interest with days to cover near 5.67 and multiple EPS estimate revisions.

$EVHMedAI 8/10

Evolent Announces Second Quarter 2026 Results

Evolent Health (NYSE: EVH) reported Q2 2026 results for the three months ended June 30, 2026 and raised 2026 revenue guidance to $2.6 to $2.7 billion and Adjusted EBITDA to $120 to $135 million. The company expects 2027 revenue growth of over 25% and Adjusted EBITDA midpoint at or above $150 million. It also outlined two partnership updates, including a $300 million annualized oncology deal.

$EVHHigh

Evolent Health, Inc. (EVH): Results of Operations and Financial Condition

Evolent Health, Inc. (EVH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2exhibit991.htm EX-99.1 Document Exhibit 99.1 Evolent Announces Second Quarter 2026 Results WASHINGTON (August 6, 2026) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex co

$LEEMed

Lee Enterprises, Incorporated Q3 2026 Earnings Call Summary

Lee Enterprises reported Q3 2026 progress toward a digital-first model, saying digital revenue was 57% of total revenue. It cited a 15% cash cost reduction and fifth straight quarter of comparable adjusted EBITDA growth, raising full-year adjusted EBITDA guidance to 22% to 28%. The company expects about $18M annual interest savings, positive net income of $5.2M, and plans debt paydown using excess cash and non-core asset sales.